vs
徕博科（LH）与Ross Stores（ROST）财务数据对比。点击上方公司名可切换其他公司
Ross Stores的季度营收约是徕博科的1.6倍（$5.6B vs $3.5B），Ross Stores净利率更高（9.1% vs 4.7%，领先4.5%），Ross Stores同比增速更快（10.4% vs 5.6%），Ross Stores自由现金流更多（$617.8M vs $490.3M），过去两年徕博科的营收复合增速更高（5.2% vs -3.6%）
徕博科（Labcorp）是全球领先的生命科学与诊断检测企业，面向医疗机构、制药企业和个人患者提供全面的临床检验服务、药物研发支持及医疗检测解决方案，依托先进科研经验与创新技术输出准确可落地的健康洞察，助力临床决策、加快新药研发，提升全球患者健康水平。
Ross Stores, Inc.是美国知名折扣百货连锁集团，旗下核心品牌为Ross Dress for Less，总部位于加利福尼亚州都柏林，是美国规模最大的平价零售商。截至2024年7月，集团在全美43个州、华盛顿特区、波多黎各及关岛共运营1795家门店，暂未覆盖新英格兰地区及阿拉斯加，另拥有门店数超353家的折扣零售品牌DD's Discounts。
LH vs ROST — 直观对比
营收规模更大
ROST
是对方的1.6倍
$3.5B
营收增速更快
ROST
高出4.8%
5.6%
净利率更高
ROST
高出4.5%
4.7%
自由现金流更多
ROST
多$127.5M
$490.3M
两年增速更快
LH
近两年复合增速
-3.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $3.5B | $5.6B |
| 净利润 | $164.7M | $511.9M |
| 毛利率 | 28.2% | 28.0% |
| 营业利润率 | 7.6% | 11.6% |
| 净利率 | 4.7% | 9.1% |
| 营收同比 | 5.6% | 10.4% |
| 净利润同比 | 14.9% | 4.7% |
| 每股收益（稀释后） | $1.98 | $1.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LHROST
| Q4 25 | $3.5B | $5.6B | ||
| Q3 25 | $3.6B | $5.5B | ||
| Q2 25 | $3.5B | $5.0B | ||
| Q1 25 | $3.3B | $5.9B | ||
| Q4 24 | $3.3B | $5.1B | ||
| Q3 24 | $3.3B | $5.3B | ||
| Q2 24 | $3.2B | $4.9B | ||
| Q1 24 | $3.2B | $6.0B |
净利润LHROST
| Q4 25 | $164.7M | $511.9M | ||
| Q3 25 | $261.1M | $508.0M | ||
| Q2 25 | $237.9M | $479.2M | ||
| Q1 25 | $212.8M | $586.8M | ||
| Q4 24 | $143.4M | $488.8M | ||
| Q3 24 | $169.3M | $527.1M | ||
| Q2 24 | $205.3M | $488.0M | ||
| Q1 24 | $228.0M | $609.7M |
毛利率LHROST
| Q4 25 | 28.2% | 28.0% | ||
| Q3 25 | 28.8% | 27.6% | ||
| Q2 25 | 29.7% | 28.2% | ||
| Q1 25 | 28.3% | 26.5% | ||
| Q4 24 | 26.9% | 28.3% | ||
| Q3 24 | 27.6% | 28.3% | ||
| Q2 24 | 28.8% | 28.1% | ||
| Q1 24 | 28.2% | 27.3% |
营业利润率LHROST
| Q4 25 | 7.6% | 11.6% | ||
| Q3 25 | 11.1% | 11.5% | ||
| Q2 25 | 11.2% | 12.2% | ||
| Q1 25 | 9.7% | 12.4% | ||
| Q4 24 | 6.5% | 11.9% | ||
| Q3 24 | 7.7% | 12.5% | ||
| Q2 24 | 9.2% | 12.2% | ||
| Q1 24 | 10.1% | 13.2% |
净利率LHROST
| Q4 25 | 4.7% | 9.1% | ||
| Q3 25 | 7.3% | 9.2% | ||
| Q2 25 | 6.7% | 9.6% | ||
| Q1 25 | 6.4% | 9.9% | ||
| Q4 24 | 4.3% | 9.6% | ||
| Q3 24 | 5.2% | 10.0% | ||
| Q2 24 | 6.4% | 10.0% | ||
| Q1 24 | 7.2% | 10.1% |
每股收益（稀释后）LHROST
| Q4 25 | $1.98 | $1.58 | ||
| Q3 25 | $3.12 | $1.56 | ||
| Q2 25 | $2.84 | $1.47 | ||
| Q1 25 | $2.52 | $1.79 | ||
| Q4 24 | $1.72 | $1.48 | ||
| Q3 24 | $2.00 | $1.59 | ||
| Q2 24 | $2.43 | $1.46 | ||
| Q1 24 | $2.69 | $1.82 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $532.3M | $4.1B |
| 总债务越低越好 | — | $1.5B |
| 股东权益账面价值 | $8.6B | $5.9B |
| 总资产 | $18.4B | $15.4B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资LHROST
| Q4 25 | $532.3M | $4.1B | ||
| Q3 25 | $598.1M | $3.8B | ||
| Q2 25 | $647.3M | $3.8B | ||
| Q1 25 | $369.4M | $4.7B | ||
| Q4 24 | $1.5B | $4.3B | ||
| Q3 24 | $1.5B | $4.7B | ||
| Q2 24 | $265.1M | $4.7B | ||
| Q1 24 | $99.3M | $4.9B |
总债务LHROST
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.5B |
股东权益LHROST
| Q4 25 | $8.6B | $5.9B | ||
| Q3 25 | $8.7B | $5.7B | ||
| Q2 25 | $8.5B | $5.6B | ||
| Q1 25 | $8.3B | $5.5B | ||
| Q4 24 | $8.1B | $5.3B | ||
| Q3 24 | $8.2B | $5.1B | ||
| Q2 24 | $8.0B | $4.9B | ||
| Q1 24 | $8.0B | $4.9B |
总资产LHROST
| Q4 25 | $18.4B | $15.4B | ||
| Q3 25 | $18.3B | $14.5B | ||
| Q2 25 | $18.1B | $14.3B | ||
| Q1 25 | $17.6B | $14.9B | ||
| Q4 24 | $18.4B | $14.9B | ||
| Q3 24 | $18.6B | $14.7B | ||
| Q2 24 | $16.7B | $14.5B | ||
| Q1 24 | $16.5B | $14.3B |
负债/权益比LHROST
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.40× | ||
| Q4 24 | — | 0.42× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 0.50× | ||
| Q1 24 | — | 0.51× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $614.2M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $490.3M | $617.8M |
| 自由现金流率自由现金流/营收 | 13.9% | 11.0% |
| 资本支出强度资本支出/营收 | 3.5% | 3.7% |
| 现金转化率经营现金流/净利润 | 3.73× | 1.62× |
| 过去12个月自由现金流最近4个季度 | $1.2B | $2.0B |
8季度趋势，按日历期对齐
经营现金流LHROST
| Q4 25 | $614.2M | $827.1M | ||
| Q3 25 | $387.2M | $668.4M | ||
| Q2 25 | $620.6M | $409.7M | ||
| Q1 25 | $18.5M | $882.6M | ||
| Q4 24 | $777.2M | $513.4M | ||
| Q3 24 | $277.3M | $592.1M | ||
| Q2 24 | $561.1M | $368.9M | ||
| Q1 24 | $-29.8M | $948.8M |
自由现金流LHROST
| Q4 25 | $490.3M | $617.8M | ||
| Q3 25 | $280.5M | $466.6M | ||
| Q2 25 | $542.7M | $202.3M | ||
| Q1 25 | $-107.5M | $676.6M | ||
| Q4 24 | $665.1M | $333.0M | ||
| Q3 24 | $161.5M | $394.6M | ||
| Q2 24 | $432.9M | $232.7M | ||
| Q1 24 | $-163.6M | $726.4M |
自由现金流率LHROST
| Q4 25 | 13.9% | 11.0% | ||
| Q3 25 | 7.9% | 8.4% | ||
| Q2 25 | 15.4% | 4.1% | ||
| Q1 25 | -3.2% | 11.4% | ||
| Q4 24 | 20.0% | 6.6% | ||
| Q3 24 | 4.9% | 7.5% | ||
| Q2 24 | 13.4% | 4.8% | ||
| Q1 24 | -5.2% | 12.1% |
资本支出强度LHROST
| Q4 25 | 3.5% | 3.7% | ||
| Q3 25 | 3.0% | 3.6% | ||
| Q2 25 | 2.2% | 4.2% | ||
| Q1 25 | 3.8% | 3.5% | ||
| Q4 24 | 3.4% | 3.6% | ||
| Q3 24 | 3.5% | 3.7% | ||
| Q2 24 | 4.0% | 2.8% | ||
| Q1 24 | 4.2% | 3.7% |
现金转化率LHROST
| Q4 25 | 3.73× | 1.62× | ||
| Q3 25 | 1.48× | 1.32× | ||
| Q2 25 | 2.61× | 0.85× | ||
| Q1 25 | 0.09× | 1.50× | ||
| Q4 24 | 5.42× | 1.05× | ||
| Q3 24 | 1.64× | 1.12× | ||
| Q2 24 | 2.73× | 0.76× | ||
| Q1 24 | -0.13× | 1.56× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LH
| Diagnostics | $2.7B | 78% |
| Biopharma Laboratory Services | $793.0M | 23% |
ROST
暂无分部数据
